Literature DB >> 17377812

Cytological diagnosis of malignant mesothelioma--improvement by additional analysis of hyaluronic acid in pleural effusions.

L Welker1, M Müller, O Holz, E Vollmer, H Magnussen, R A Jörres.   

Abstract

Cytology allows the diagnosis of malignant mesothelioma (MM) from effusions with high specificity but low sensitivity. Conversely, elevated levels of hyaluronic acid (HA) in effusions are sensitive indicators of MM, although specificity is insufficient. We studied whether the cytological diagnosis of MM could be improved by HA analysis. HA was analysed in patients with histologically confirmed MM (n=162), adenocarcinoma or other malignant tumours (n=100) and in 90 patients with benign pleural diseases. In 77 out of 162 effusions, all, and in 33 some, cytological criteria of MM were satisfied. The cut-off value of HA showing maximum diagnostic reliability (86%) regarding MM was 30 mg/l (sensitivity 87%, specificity 86%). A HA value of 100 mg/l yielded 39 and 98%, respectively. Seventy three out of 77 patients with cytological findings indicative of MM showed HA levels greater than 30 mg/l as well as 27 of 33 patients with suspicious lesions. These 100 patients were correctly recognised as having MM. The addition of HA analysis to cytology, requiring all or some criteria of MM as positive, increased sensitivity for MM from 48 to 71-91%, whereas specificity only slightly decreased to 94-96%. We conclude that the combined cytological and HA analysis of pleural effusions had the potential to improve the diagnosis of MM.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17377812     DOI: 10.1007/s00428-007-0375-x

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  18 in total

1.  Acid glycosaminoglycans (mucopolysaccharides) in the differential diagnosis of pleural effusion.

Authors:  C Friman; P E Hellström; M Juvani; H Riska
Journal:  Clin Chim Acta       Date:  1977-05-02       Impact factor: 3.786

2.  A longitudinal study of the hyaluronan level in the serum of patients with malignant mesothelioma under treatment. Hyaluronan as an indicator of progressive disease.

Authors:  I M Dahl; O P Solheim; B Erikstein; E Müller
Journal:  Cancer       Date:  1989-07-01       Impact factor: 6.860

Review 3.  Immunological mechanisms in pleural disease.

Authors:  V B Antony
Journal:  Eur Respir J       Date:  2003-03       Impact factor: 16.671

4.  The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma.

Authors:  A A Renshaw; B R Dean; K H Antman; D J Sugarbaker; E S Cibas
Journal:  Chest       Date:  1997-01       Impact factor: 9.410

5.  Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignancies.

Authors:  C Fuhrman; J C Duche; C Chouaid; I Abd Alsamad; K Atassi; I Monnet; J P Tillement; B Housset
Journal:  Clin Biochem       Date:  2000-07       Impact factor: 3.281

6.  Utility of hyaluronic acid in pleural fluid for differential diagnosis of pleural effusions: likelihood ratios for malignant mesothelioma.

Authors:  S Atagi; M Ogawara; M Kawahara; M Sakatani; K Furuse; E Ueda; S Yamamoto
Journal:  Jpn J Clin Oncol       Date:  1997-10       Impact factor: 3.019

7.  Predictive value of BAL cell differentials in the diagnosis of interstitial lung diseases.

Authors:  L Welker; R A Jörres; U Costabel; H Magnussen
Journal:  Eur Respir J       Date:  2004-12       Impact factor: 16.671

8.  Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma.

Authors:  T Pettersson; B Fröseth; H Riska; M Klockars
Journal:  Chest       Date:  1988-11       Impact factor: 9.410

9.  Biochemical and cytological features of diffuse mesotheliomas of the pleura.

Authors:  W Matzel
Journal:  Arch Geschwulstforsch       Date:  1985

10.  The European mesothelioma epidemic.

Authors:  J Peto; A Decarli; C La Vecchia; F Levi; E Negri
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

View more
  15 in total

Review 1.  Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.

Authors:  Nico van Zandwijk; Christopher Clarke; Douglas Henderson; A William Musk; Kwun Fong; Anna Nowak; Robert Loneragan; Brian McCaughan; Michael Boyer; Malcolm Feigen; David Currow; Penelope Schofield; Beth Ivimey Nick Pavlakis; Jocelyn McLean; Henry Marshall; Steven Leong; Victoria Keena; Andrew Penman
Journal:  J Thorac Dis       Date:  2013-12       Impact factor: 2.895

Review 2.  Molecular markers and new diagnostic methods to differentiate malignant from benign mesothelial pleural proliferations: a literature review.

Authors:  Rossella Bruno; Greta Alì; Gabriella Fontanini
Journal:  J Thorac Dis       Date:  2018-01       Impact factor: 2.895

3.  Cytological Diagnostic Procedures in Malignant Mesothelioma.

Authors:  Christian Biancosino; Lea Isabell Shari van der Linde; Guido Sauter; Florian Stellmacher; Marcus Krüger; Lutz Welker
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

4.  Secretion of intelectin-1 from malignant pleural mesothelioma into pleural effusion.

Authors:  S Tsuji; Y Tsuura; T Morohoshi; T Shinohara; F Oshita; K Yamada; Y Kameda; T Ohtsu; Y Nakamura; Y Miyagi
Journal:  Br J Cancer       Date:  2010-07-13       Impact factor: 7.640

5.  Protumorigenic role of HAPLN1 and its IgV domain in malignant pleural mesothelioma.

Authors:  Alla V Ivanova; Chandra M V Goparaju; Sergey V Ivanov; Daisuke Nonaka; Christina Cruz; Amanda Beck; Fulvio Lonardo; Anil Wali; Harvey I Pass
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

6.  Effects of hyaluronic acid and CD44 interaction on the proliferation and invasiveness of malignant pleural mesothelioma.

Authors:  Takeshi Hanagiri; Shinji Shinohara; Masaru Takenaka; Yoshiki Shigematsu; Manabu Yasuda; Hidehiko Shimokawa; Yoshika Nagata; Makoto Nakagawa; Hidetaka Uramoto; Tomoko So; Fumihiro Tanaka
Journal:  Tumour Biol       Date:  2012-08-11

7.  A seven-year disease-free survivor of malignant pleural mesothelioma treated with hyperthermia and chemotherapy: a case report.

Authors:  Noriyuki Okonogi; Takeshi Ebara; Hitoshi Ishikawa; Daisaku Yoshida; Manabu Ueno; Toshitaka Maeno; Tatsuo Suga; Takashi Nakano
Journal:  J Med Case Rep       Date:  2012-12-28

8.  Tissue hyaluronan expression, as reflected in the sputum of lung cancer patients, is an indicator of malignancy.

Authors:  M P Rangel; V K de Sá; V Martins; J R M Martins; E R Parra; A Mendes; P C Andrade; R M Reis; A Longatto-Filho; C Z Oliveira; T Takagaki; D M Carraro; H B Nader; V L Capelozzi
Journal:  Braz J Med Biol Res       Date:  2015-05-08       Impact factor: 2.590

9.  The diagnostic role of glycosaminoglycans in pleural effusions: a pilot study.

Authors:  Rozina Vavetsi; Stefanos Bonovas; Paraskevi Polizou; Chrysanthi Papanastasopoulou; Georgia Dougekou; Nikolaos M Sitaras
Journal:  BMC Pulm Med       Date:  2009-02-18       Impact factor: 3.317

10.  Parakeratotic-like cells in effusions - A clue to diagnosis of malignant mesothelioma.

Authors:  Ling Gao; Ward Reeves; Richard M Demay
Journal:  Cytojournal       Date:  2012-07-28       Impact factor: 2.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.